There is also preclinical evidence that hyperinsulinemia can lead to partial reactivation of PI3K signaling; hence, administering insulin may theoretically interfere with the therapeutic activity of alpelisib [4]. This evidence concerns the gene PIK3CB and hyperinsulinism.